Ki Katrina K, Passmore Margaret R, Chan Chris H H, Malfertheiner Maximilian V, Fanning Jonathon P, Bouquet Mahé, Millar Jonathan E, Fraser John F, Suen Jacky Y
Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia.
Faculty of Medicine, University of Queensland, Brisbane, Australia.
Intensive Care Med Exp. 2019 Aug 20;7(1):51. doi: 10.1186/s40635-019-0264-z.
Extracorporeal membrane oxygenation (ECMO) is a life-saving modality used to manage cardiopulmonary failure refractory to conventional medical and surgical therapies. Despite advances in ECMO equipment, bleeding and thrombosis remain significant complications. While the flow rate for ECMO support is well recognized, less is known about the minimum-rate requirements and haemostasis. We investigated the relationship between different ECMO flow rates, and their effect on haemolysis and coagulation.
Ten ex-vivo ECMO circuits were tested using donated, < 24-h-old human whole blood, with two flow rates: high-flow at 4 L/min (normal adult cardiac output; n = 5) and low-flow at 1.5 L/min (weaning; n = 5). Serial blood samples were taken for analysis of haemolysis, von Willebrand factor (vWF) multimers by immunoblotting, rotational thromboelastometry, platelet aggregometry, flow cytometry and routine coagulation laboratory tests.
Low-flow rates increased haemolysis after 2 h (p = 0.02), 4 h (p = 0.02) and 6 h (p = 0.02) and the loss of high-molecular-weight vWF multimers (p = 0.01), while reducing ristocetin-induced platelet aggregation (p = 0.0002). Additionally, clot formation times were prolonged (p = 0.006), with a corresponding decrease in maximum clot firmness (p = 0.006).
In an ex-vivo model of ECMO, low-flow rate (1.5 L/min) altered haemostatic parameters compared to high-flow (4 L/min). Observed differences in haemolysis, ristocetin-induced platelet aggregation, high-molecular-weight vWF multimers and clot formation time suggest an increased risk of bleeding complications. Since patients are often on ECMO for protracted periods, extended-duration studies are required to characterise long-term ECMO-induced haemostatic changes.
体外膜肺氧合(ECMO)是一种用于治疗常规内科和外科治疗无效的心肺衰竭的挽救生命的方式。尽管ECMO设备有所进步,但出血和血栓形成仍然是严重的并发症。虽然ECMO支持的流速已广为人知,但关于最低流速要求和止血的了解较少。我们研究了不同ECMO流速之间的关系及其对溶血和凝血的影响。
使用捐献的、保存时间小于24小时的人全血对10个体外ECMO回路进行测试,设置两种流速:高流速4L/min(正常成人心输出量;n = 5)和低流速1.5L/min(撤机;n = 5)。采集系列血样用于分析溶血、通过免疫印迹法检测血管性血友病因子(vWF)多聚体、旋转血栓弹力图、血小板聚集试验、流式细胞术和常规凝血实验室检查。
低流速在2小时(p = 0.02)、4小时(p = 0.02)和6小时(p = 0.02)后增加了溶血,并导致高分子量vWF多聚体丢失(p = 0.01),同时降低了瑞斯托霉素诱导的血小板聚集(p = 0.0002)。此外,凝血形成时间延长(p = 0.006),最大凝血硬度相应降低(p = 0.006)。
在ECMO的体外模型中,与高流速(4L/min)相比,低流速(1.5L/min)改变了止血参数。观察到的溶血、瑞斯托霉素诱导的血小板聚集、高分子量vWF多聚体和凝血形成时间的差异表明出血并发症风险增加。由于患者通常需要长时间使用ECMO,因此需要进行长期研究以确定长期ECMO诱导的止血变化特征。